1:1 Atrial flutter after vernakalant administration for atrial fibrillation cardioversion;Flutter auricular 1:1 tras la administración de vernakalant para cardioversión de fibrilación auricular

Revista Espanola de Cardiologia

Volumn 65, Issue 11, 2012, Pages 1062-1064

  De Riva Silva, Marta ^a   Montero Cabezas, José M ^a   Salgado Aranda, Ricardo ^a   López Gil, María ^a   Fontenla Cerezuela, Adolfo ^a   Arribas Ynsaurriaga, Fernando ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

VERNAKALANT;

CARDIOVERSION; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; LETTER;

AGED; ANISOLES; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; ELECTRIC COUNTERSHOCK; ELECTROCARDIOGRAPHY; HEART CONDUCTION SYSTEM; HUMANS; MALE; PYRROLIDINES; SODIUM CHANNEL BLOCKERS;

EID: 84867572781     PISSN: 03008932     EISSN: 15792242     Source Type: Journal    
DOI: 10.1016/j.recesp.2012.03.015     Document Type: Letter

References (6)

1. A. Nabar, L. Rodríguez, Timmermans, R. Van Mechelen, and H. Wellens Class IC antiarrhythmic drug induced atrial flutter: electrocardiographic and electrophysiological findings and their importance for long term outcome after right atrial isthmus ablation Heart 85 2001 424 429 (Pubitemid 32973531)
2. D. Roy, D. Pratt, C. Torp-Pedersen, D. Wyse, E. Toft, and S. Juul-Moller Vernakalant hydrochloride for rapid conversion of atrial fibrillation: a phase 3, randomized, placebo-controlled trial Circulation 117 2008 1518 1525 (Pubitemid 351440640)
3. A. Hernández Madrid, R. Matía Francés, and C. Moro Novedades en electrofisiología cardiaca y arritmias Rev Esp Cardiol 64 Suppl 1 2011 81 90
4. A.J. Camm, A. Capucci, S.H. Hohnloser, C. Torp-Pedersen, I.C. Van Gelder, and B. Mangal A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation J Am Coll Cardiol 57 2011 313 321
5. A.J. Camm, E. Toft, C. Torp-Pedersen, P. Vijayaraman, S. Juul-Moller, and J. Ip Efficacy and safety of vernakalant in patients with atrial flutter: a randomized, double blind, placebo-controlled trial Europace 14 2012 804 809
6. P. Dorian, A. Pinter, I. Mangat, V. Korley, S.S. Cvitkovic, and G.N. Beatch The effect of vernakalant (RSD1235), an investigational antiarrhythmic agent, on atrial electrophysiology in humans J Cardiovasc Pharmacol 50 2007 35 40 (Pubitemid 47220444)